SOURCE: NexMed, Inc.

August 03, 2006 09:02 ET

NexMed Maintains Nasdaq Listing

Company to Report Second Quarter Financial Results on Monday, August 14, 2006

EAST WINDSOR, NJ -- (MARKET WIRE) -- August 3, 2006 -- NexMed, Inc. (NASDAQ: NEXM), a developer of innovative treatments based on the NexACT® technology, today announced that it received a letter from Nasdaq yesterday stating that the market capitalization deficiency of NexMed has been cured. Accordingly, NexMed's oral hearing scheduled for Thursday, August 17, 2006 is considered moot.

Conference Call

NexMed management also announced today that the Company will host a conference call on Monday, August 14, 2006 at 10:00 a.m. EDT, during which management will review second quarter financial results, and expected development advances of its partnered anti-fungal product in 2006. The Company intends to file its Form 10-Q for the quarter ended June 30, 2006 today. The call can be accessed in the U.S. by dialing 877-407-9205 and outside of the U.S. by dialing 201-689-8054, and asking the conference operator for the NexMed Conference Call. The teleconference replay is available for one week by dialing in the U.S. 877-660-6853 and outside of the U.S. by dialing 201-612-7415. Replay pass codes 286 and 210462 are both required for playback. The conference call will also be Webcast live at URL

About NexMed, Inc.

NexMed, an innovative drug developer, offers large pharmaceutical companies the opportunity to develop new patient-friendly transdermal products, and extend patent lifespan and brand equity, through participation in early stage licensing and development partnerships. NexMed currently has a host of medicines in development, such as treatments for nail fungus, sexual disorders and more, all based on its proprietary NexACT® drug delivery technology.

Contact Information

  • Company Contact:
    Deborah Carty
    NexMed, Inc.
    (609) 371-8123, ext: 159
    Email Contact

    Investor Relations:
    Paula Schwartz
    Rx Communications Group, LLC
    (917) 322-2216
    Email Contact